20.95
+0.69(+3.41%)
Currency In USD
Address
One Broadway
Cambridge, MA 02142
United States of America
Phone
617 514 7149
Website
Sector
Healthcare
Industry
Biotechnology
Employees
159
First IPO Date
March 05, 2015
| Name | Title | Pay | Year Born |
| Mr. Robert W. Duggan | Co-Chief Executive Officer & Executive Chairman | 158,613 | 1945 |
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-Chief Executive Officer, President & Director | 1.16M | 1970 |
| Mr. Manmeet Singh Soni CPA | Chief Operating Officer, Chief Financial Officer & Director | 1.26M | 1978 |
| Dr. Fong Clow | Chief Biometrics Officer | 0 | N/A |
| Ms. Shelley D. Spray | Chief Education & Brand Officer | 0 | 1965 |
| Dr. Urte Gayko Ph.D. | Chief Regulatory, Quality & Pharmacovigilance Officer | 0 | 1971 |
| Dr. Laura Q. M. Chow M.D. | Senior Vice President of Clinical Development | 0 | N/A |
| Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | 0 | 1951 |
| Mr. Dave Gancarz | Chief Business & Strategy Officer | 0 | N/A |
| Dr. Allen S. Yang M.D., Ph.D. | Chief Medical Officer | 0 | 1968 |
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.